U.S. NeuroSurgical Holdings, Inc. (USNU)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
U.S. NeuroSurgical Holdings, Inc. (USNU) trades at $1.03. U. S. NeuroSurgical Holdings, Inc. Market cap: $22.16M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for USNU: USNU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates USNU against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
USNU: 1/1 perspectives are bearish.
How is this calculated? →U.S. NeuroSurgical Holdings, Inc. (USNU) Healthcare & Pipeline Overview
U.S. NeuroSurgical Holdings, Inc. focuses on stereotactic radiosurgery using gamma knife technology, offering non-invasive brain tumor treatment. Operating in a specialized medical niche, the company's small size and OTC listing present unique investment considerations within the broader healthcare landscape.
What Is the Investment Thesis for USNU?
Investing in U.S. NeuroSurgical Holdings, Inc. presents a high-risk, high-reward scenario. The company's specialization in gamma knife radiosurgery offers a niche market position. However, the company's negative profit margin of -382.8% and OTC listing require careful consideration. Growth catalysts include potential expansion of services and increased adoption of gamma knife technology. Key risks include limited financial resources, competition, and regulatory hurdles. The company's small market capitalization of $22.16M and low beta of 0.50 suggest limited volatility, but also limited liquidity.
Based on FMP financials and quantitative analysis
USNU Key Highlights
- Market capitalization of $22.16M indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -7.38 reflects current unprofitability, requiring investors to focus on future earnings potential.
- Gross margin of 48.9% suggests a viable core business, but high operating costs contribute to a negative profit margin of -382.8%.
- Beta of 0.50 indicates lower volatility compared to the overall market.
- The company does not offer a dividend, typical for growth-focused or financially constrained companies.
Who Are USNU's Competitors?
USNU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DIZTF Dignitana AB (publ) | $0.22 | +0.00% | $17.99M | 49 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.73M | 44 |
| HDSLF HS GovTech Solutions Inc. | $0.39 | -0.39% | $21.13M | 46 |
| HQDA HQDA Elderly Life Network Corp. | $0.13 | +2.84% | $18.64M | — |
| KBBTF Kubota Pharmaceutical Holdings Co., Ltd. | $0.96 | +0.00% | $24.10M | 46 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are USNU's Key Strengths?
- Specialized expertise in gamma knife radiosurgery.
- Non-invasive treatment option for brain tumors.
- Established operational centers.
What Are USNU's Weaknesses?
- Small market capitalization and limited financial resources.
- Negative profit margin.
- Reliance on a single technology.
What Could Drive USNU Stock Higher?
- Potential expansion of gamma knife centers into new geographic markets.
- Strategic partnerships with hospitals and medical centers to broaden patient reach.
- Technological advancements in radiosurgery to improve treatment outcomes and attract patients.
What Are the Key Risks for USNU?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger hospitals and medical centers with more resources.
- Regulatory changes and healthcare reforms impacting reimbursement rates.
- Technological obsolescence of gamma knife technology.
- Limited financial resources and negative profit margin.
- Risks associated with OTC market trading, including low liquidity and limited disclosure.
What Are the Growth Opportunities for USNU?
- Expansion of Gamma Knife Centers: U.S. NeuroSurgical Holdings, Inc. could expand by establishing new gamma knife centers in underserved geographic areas. The market for radiosurgery is projected to grow as the population ages and demand for non-invasive treatments increases. This expansion would require significant capital investment but could substantially increase revenue and market share. The timeline for establishing new centers is estimated at 12-18 months per location.
- Strategic Partnerships with Hospitals: Forming strategic partnerships with existing hospitals and medical centers could provide U.S. NeuroSurgical Holdings, Inc. with access to a broader patient base and shared resources. This would allow the company to leverage the existing infrastructure and referral networks of partner hospitals. The timeline for establishing such partnerships is estimated at 6-12 months per partnership.
- Technological Upgrades and Innovation: Investing in the latest gamma knife technology and developing innovative treatment protocols could attract more patients and differentiate U.S. NeuroSurgical Holdings, Inc. from competitors. Continuous technological advancement is crucial in the medical field to maintain a competitive edge. The timeline for implementing technological upgrades is ongoing, with new advancements emerging regularly.
- Marketing and Outreach Programs: Implementing targeted marketing and outreach programs to educate potential patients and referring physicians about the benefits of gamma knife radiosurgery could increase patient volume. This includes online advertising, participation in medical conferences, and direct outreach to neurologists and oncologists. The timeline for seeing results from marketing efforts is estimated at 3-6 months.
- Telemedicine and Remote Consultation Services: Offering telemedicine and remote consultation services could expand the company's reach to patients in remote areas or those who have difficulty traveling to a treatment center. This would leverage technology to overcome geographical barriers and increase accessibility to the company's services. The timeline for implementing telemedicine services is estimated at 3-6 months.
What Opportunities Does USNU Have?
- Expansion into new geographic markets.
- Strategic partnerships with hospitals and medical centers.
- Technological advancements in radiosurgery.
What Threats Does USNU Face?
- Competition from larger hospitals and medical centers.
- Regulatory changes and healthcare reforms.
- Technological obsolescence.
What Are USNU's Competitive Advantages?
- Specialized Gamma Knife Technology: Gamma knife technology provides a non-invasive alternative to traditional brain surgery.
- Expertise in Stereotactic Radiosurgery: The company's focus on stereotactic radiosurgery creates a niche market position.
- Established Centers: The company owns and operates stereotactic radiosurgery centers.
What Does USNU Do?
U.S. NeuroSurgical Holdings, Inc., established in 1993 and based in Rockville, Maryland, specializes in operating stereotactic radiosurgery centers. The company's core offering revolves around the use of gamma knife technology, a sophisticated method for treating brain tumors and other brain malformations without the need for traditional invasive surgery. This technology allows for precise targeting of affected areas, minimizing damage to surrounding healthy tissue. The company's business model centers on providing these specialized radiosurgery services to patients requiring treatment for various neurological conditions. As of 2026, the company has a small team of 3 employees. The gamma knife procedure is a non-invasive alternative to traditional brain surgery, offering patients a potentially less risky and more comfortable treatment option. U.S. NeuroSurgical Holdings, Inc. aims to provide advanced neurosurgical solutions through its specialized centers.
What Products and Services Does USNU Offer?
- Operates stereotactic radiosurgery centers.
- Utilizes gamma knife technology for brain tumor treatment.
- Provides non-invasive alternatives to traditional brain surgery.
- Offers treatment for various malformations of the brain.
- Focuses on precise targeting of affected areas to minimize damage to healthy tissue.
- Provides specialized radiosurgery services to patients requiring neurological treatment.
How Does USNU Make Money?
- Generates revenue by providing gamma knife radiosurgery treatments.
- Operates specialized medical centers equipped with gamma knife technology.
- Partners with physicians and hospitals for patient referrals.
What Industry Does USNU Operate In?
U.S. NeuroSurgical Holdings, Inc. operates within the medical care facilities industry, a segment of the broader healthcare sector. This industry is characterized by increasing demand for specialized medical treatments and an aging population. The competitive landscape includes larger hospital systems and specialized treatment centers. U.S. NeuroSurgical Holdings, Inc. differentiates itself through its focus on gamma knife radiosurgery, a niche market within neurosurgery. The industry is subject to stringent regulatory oversight and technological advancements, requiring continuous investment and adaptation.
Who Are USNU's Key Customers?
- Patients with brain tumors and other brain malformations.
- Neurologists and oncologists who refer patients for radiosurgery.
- Hospitals and medical centers seeking specialized neurosurgical services.
U.S. NeuroSurgical Holdings, Inc. (USNU) Valuation Context
Valued at $22.16M, USNU is classified as a micro-cap stock.
USNU Revenue & Earnings Trend
In Q1 2026, USNU generated $1.4M in top-line revenue, marking a sequential increase of 36.5%. The company recorded a net loss of $1.3M, with diluted EPS of $-0.05. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, USNU averaged $-0.09 in diluted EPS.
Company Profile
U.S. NeuroSurgical Holdings, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Ontario, US. The company is led by CEO Jeereddi Anjaneya Prasad. USNU has traded publicly since 2007.
Key Financial Metrics
Its free cash flow yield is -17.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
U.S. NeuroSurgical Holdings, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.05 places it in the safe zone, indicating low near-term bankruptcy risk.
Net buyingInsider Activity
The most recent 10 insider filings for U.S. NeuroSurgical Holdings, Inc. break down as 3 sales and 7 purchases. On net that is roughly 456K shares acquired (about $5K) — insiders putting money in tends to read as conviction.
USNU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized expertise in gamma knife radiosurgery.
- Non-invasive treatment option for brain tumors.
- Established operational centers.
- Upcoming: Potential expansion of gamma knife centers into new geographic markets.
Bear Case
- Small market capitalization and limited financial resources.
- Negative profit margin.
- Reliance on a single technology.
- Potential: Competition from larger hospitals and medical centers with more resources.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1M | -$1M | -$0.05 |
| Q4 2025 | $1M | -$6M | -$0.26 |
| Q3 2025 | $0 | -$1M | -$0.05 |
| Q2 2025 | $0 | -$441,000 | -$0.02 |
Based on FMP financials and quantitative analysis
USNU Latest News
No recent news available for USNU.
USNU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for USNU.
Price Targets
Wall Street price target analysis for USNU.
USNU MoonshotScore
What does this score mean?
The MoonshotScore rates USNU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeereddi Anjaneya Prasad
CEO
Jeereddi Anjaneya Prasad serves as the CEO of U.S. NeuroSurgical Holdings, Inc. Information regarding Mr. Prasad's detailed career history, educational background, and previous roles is not available in the provided data. As CEO, he is responsible for the overall strategic direction and operational management of the company, overseeing its stereotactic radiosurgery centers and the utilization of gamma knife technology. He manages a small team of 3 employees.
Track Record: Due to limited information, it is not possible to assess Mr. Prasad's specific achievements, strategic decisions, or company milestones under his leadership. His tenure and impact on the company's performance remain unknown based on the available data.
USNU OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that U.S. NeuroSurgical Holdings, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in OTC Other stocks requires careful due diligence and an understanding of the associated risks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or bankruptcy.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's legal registration and compliance status.
- Review available financial statements and assess the company's financial health.
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market opportunities.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1993.
- The company owns and operates stereotactic radiosurgery centers.
- The company utilizes gamma knife technology for brain tumor treatment.
What Investors Ask About U.S. NeuroSurgical Holdings, Inc. (USNU) — Healthcare
What does U.S. NeuroSurgical Holdings, Inc. do?
U.S. NeuroSurgical Holdings, Inc. operates stereotactic radiosurgery centers, specializing in the use of gamma knife technology for the non-invasive treatment of brain tumors and other brain malformations. Their business model centers around providing these specialized radiosurgery services, offering a less invasive alternative to traditional brain surgery. The company generates revenue by treating patients requiring neurological interventions, partnering with physicians and hospitals for referrals. The company's focus on gamma knife technology creates a niche market position within the broader healthcare landscape.
What do analysts say about USNU stock?
As of March 18, 2026, formal analyst ratings and price targets for U.S. NeuroSurgical Holdings, Inc. (USNU) are unavailable, likely due to its OTC listing and small market capitalization. Key valuation metrics to consider include the company's negative P/E ratio of -7.38 and profit margin of -382.8%, indicating current unprofitability. Investors should focus on the company's potential for growth, its competitive position in the radiosurgery market, and its ability to improve financial performance. Due diligence and independent research are crucial for evaluating this stock.
What are the main risks for USNU?
U.S. NeuroSurgical Holdings, Inc. faces several key risks, including its small market capitalization, negative profit margin, and reliance on a single technology (gamma knife). Competition from larger hospitals and medical centers with greater resources poses a significant threat. Regulatory changes and healthcare reforms could impact reimbursement rates and treatment protocols. The company's OTC listing carries additional risks, such as low liquidity, limited disclosure, and potential for price volatility. Investors should carefully consider these factors before investing.
What are the key factors to evaluate for USNU?
Evaluate USNU on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does USNU data refresh on this page?
USNU prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven USNU's recent stock price performance?
U.S. NeuroSurgical Holdings, Inc. (USNU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in gamma knife radiosurgery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider USNU overvalued or undervalued right now?
Valuing U.S. NeuroSurgical Holdings, Inc. (USNU) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying USNU?
Before investing in U.S. NeuroSurgical Holdings, Inc. (USNU), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- Disclosure status on OTC market is unknown, impacting transparency.
- AI analysis pending, limiting comprehensive insights.